ARA-290 vs TB-500
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
- Half-Life
- ~2–4 hours (SC administration)
- 2–3 hours
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 2–2.5 mg
- Frequency
- Once daily
- Twice weekly
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Enhances muscle tissue regeneration
- Accelerates healing of wounds and injuries
- Reduces inflammation and pain
- Improves flexibility and mobility
- Promotes new blood vessel formation
- Supports hair growth and skin health
- May improve cardiac function after injury
- Systemic healing effect — works at distance from injection site
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Injection site discomfort
- Fatigue (rare)
- Headache (rare)
- Stacks With
- —
- —